Oxigene Inc.
701 Gateway Boulevard
Suite 210
South San Francisco,
CA 94080
United States - Map
Phone: 650-635-7000
Fax: 650-635-7001
Web Site: http://www.oxigene.com
| OXiGENE, Inc., a biopharmaceutical company, develops small-molecule therapeutics to treat cancer and eye diseases in the United States. It focuses on the development and commercialization of drug candidates that disrupt abnormal blood vessels associated with solid tumor progression and visual impairment in ocular diseases. The companys product ZYBRESTAT, which is in Phase II/III pivotal registration study as a potential treatment for anaplastic thyroid cancer, as well as in Phase II clinical trials for other solid tumors, including non-small cell lung cancer and platinum resistant ovarian cancer. It also develops a topical formulation of ZYBRESTAT for ophthalmological diseases and conditions, such as age-related macular degeneration. In addition, OXiGENE develops OXi4503, which is in Phase I clinical trial for solid tumors. It has a strategic collaboration agreement with Symphony Capital Partners, L.P. to support the advancement of ZYBRESTAT for oncology and ophthalmology. The company was founded in 1988 and is headquartered in Waltham, Massachusetts. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. James B. Murphy , 52
Chief Financial Officer, Principal Accounting Officer and VP |
N/A
| N/A | Dr. David Chaplin Ph.D., 53
Chief Scientific Officer |
N/A
| N/A | Dr. Peter J. Langecker M.D., Ph.D., 58
Interim Chief Exec. Officer, Chief Devel. Officer and Exec. VP |
N/A
| N/A | Ms. Shari Annes ,
Exec. Officer of Investor Relations |
N/A
| N/A | Dr. Peter Harris M.D., 65
Consultant |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.48% Nasdaq 
Profile
